These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

571 related items for PubMed ID: 19336954

  • 1. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection.
    Yanagihara K, Izumikawa K, Higa F, Tateyama M, Tokimatsu I, Hiramatsu K, Fujita J, Kadota J, Kohno S.
    Intern Med; 2009; 48(7):527-35. PubMed ID: 19336954
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A randomized controlled non-inferiority trial of placebo versus macrolide antibiotics for Mycoplasma pneumoniae infection in children with community-acquired pneumonia: trial protocol for the MYTHIC Study.
    Meyer Sauteur PM, Seiler M, Tilen R, Osuna E, von Wantoch M, Sidorov S, Aebi C, Agyeman P, Barbey F, Bielicki JA, Coulon L, Deubzer B, Donas A, Heininger U, Keitel K, Köhler H, Kottanattu L, Lauener R, Niederer-Loher A, Posfay-Barbe KM, Tomaske M, Wagner N, Zimmermann P, Zucol F, von Felten S, Berger C.
    Trials; 2024 Oct 03; 25(1):655. PubMed ID: 39363201
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.
    Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, Plouffe JF, Rakowsky A, Schuchat A, Whitney CG.
    Arch Intern Med; 2000 May 22; 160(10):1399-408. PubMed ID: 10826451
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [The clinical characteristics, treatment and outcome of macrolide-resistant Mycoplasma pneumoniae pneumonia in children].
    Bao F, Qu JX, Liu ZJ, Qin XG, Cao B.
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Oct 22; 36(10):756-61. PubMed ID: 24433804
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
    Patel T, Pearl J, Williams J, Haverstock D, Church D.
    Respir Med; 2000 Feb 22; 94(2):97-105. PubMed ID: 10714413
    [Abstract] [Full Text] [Related]

  • 14. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability.
    Lode H, File TM, Mandell L, Ball P, Pypstra R, Thomas M, 185 Gemifloxacin Study Group.
    Clin Ther; 2002 Nov 22; 24(11):1915-36. PubMed ID: 12501883
    [Abstract] [Full Text] [Related]

  • 15. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
    Jones RN, Sader HS, Stilwell MG, Fritsche TR.
    Diagn Microbiol Infect Dis; 2007 May 22; 58(1):1-7. PubMed ID: 17408904
    [Abstract] [Full Text] [Related]

  • 16. [In vitro resistance rates of Streptococcus pneumoniae and Haemophilus influenzae clinical isolates to the antibiotics used in therapy].
    Uncu H, Colakoğlu S, Turunç T, Demiroğlu YZ, Arslan H.
    Mikrobiyol Bul; 2007 Jul 22; 41(3):441-6. PubMed ID: 17933256
    [Abstract] [Full Text] [Related]

  • 17. Clinical and bacteriological efficacies of sitafloxacin against community-acquired pneumonia caused by Streptococcus pneumoniae: nested cohort within a multicenter clinical trial.
    Fujita J, Niki Y, Kadota J, Yanagihara K, Kaku M, Watanabe A, Aoki N, Hori S, Tanigawara Y, Cash HL, Kohno S.
    J Infect Chemother; 2013 Jun 22; 19(3):472-9. PubMed ID: 23179958
    [Abstract] [Full Text] [Related]

  • 18. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ, Giménez MJ, Barberán J, Coronel P, Gimeno M, Aguilar L.
    Clin Ther; 2006 Dec 22; 28(12):2061-9. PubMed ID: 17296462
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials.
    Fogarty CM, Greenberg RN, Dunbar L, Player R, Marrie TJ, Kojak CM, Morgan N, Williams RR.
    Clin Ther; 2001 Mar 22; 23(3):425-39. PubMed ID: 11318077
    [Abstract] [Full Text] [Related]

  • 20. Antibacterial activity and PK/PD of ceftriaxone against penicillin-resistant Streptococcus pneumoniae and beta-lactamase-negative ampicillin-resistant Haemophilus influenzae isolates from patients with community-acquired pneumonia.
    Ohno A, Ishii Y, Kobayashi I, Yamaguchi K.
    J Infect Chemother; 2007 Oct 22; 13(5):296-301. PubMed ID: 17982717
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.